FDA Drug Recalls

Recalls / Firms / Daiichi Sankyo Pharma Development

Daiichi Sankyo Pharma Development

8 FDA drug recalls on record.

DateClassDrugStatus
2014-07-12Class IIBenicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/12.5 mg, 30 count botTerminated
2014-07-12Class IIBenicar Tablets (olmesartan medoxomil) 40 mg, 30 and 90 count, Rx Only Manufactured for: DTerminated
2014-07-12Class IIBenicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/25 mg, 30 and 90 counTerminated
2014-07-12Class IIBenicar Tablets (olmesartan medoxomil) 20 mg, 30 and 90 count, Rx Only Manufactured for: DTerminated
2014-07-12Class IIBenicar HCT Tablets (olmesartan medoxomil, hydrochlorothiazide) 20 mg/12.5 mg, 30 count boTerminated
2014-07-12Class IITribenzor Tablets (olmesartan medoxomil/amlodipine/hydrochlorothiazide), 40 mg/5 mg*/25 mgTerminated
2014-07-12Class IIAzor Tablets (amlodipine and olmesartan medoxomil) 10 mg*/40 mg, 30 count bottles, Rx OnlyTerminated
2014-07-12Class IIWelchol Tablets (colesevelam HCl) 625 mg, 180 count bottles, Rx Only, Manufactured for: DaTerminated
Daiichi Sankyo Pharma Development — FDA drug recalls (8) · FDA Drug Recalls